A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors

Bioorganic and Medicinal Chemistry

Volumn 28, Issue 5, 2020, Pages

  Kaur, Sukhvir ^a   Bansal, Yogita ^a   Kumar, Raj ^b   Bansal, Gulshan ^a  

^a PUNJABI UNIVERSITY   (India)

^b CENTRAL UNIVERSITY OF PUNJAB   (India)

Author keywords

Inflammation; Inhibitor; Interleukin 6; JAK STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; CLAZAKIZUMAB; CYTOKINE RECEPTOR ANTAGONIST; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE INHIBITOR; METHYL 2 (4' METHOXY 4 OXOBUTANAMIDE)BENZOIC ACID; MONOCLONAL ANTIBODY; OLOKIZUMAB; PF 423691; PROTEIN TYROSINE KINASE INHIBITOR; SARILUMAB; SILTUXIMAB; SIRUKUMAB; STAT3 INHIBITOR; TOCILIZUMAB; UNCLASSIFIED DRUG;

AKT SIGNALING; ALZHEIMER DISEASE; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANKYLOSING SPONDYLITIS; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ASTHMA; CACHEXIA; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG STRUCTURE; HEART ARREST; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALIGNANT NEOPLASM; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; OVARY CANCER; PATHOPHYSIOLOGY; POLYCHONDRITIS; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOLID MALIGNANT NEOPLASM; ANIMAL; CHEMISTRY; IMMUNOLOGY; MOLECULAR MODEL;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INTERLEUKIN-6; MODELS, MOLECULAR;

EID: 85078263754     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2020.115327     Document Type: Review

References (162)

1. Ryan, G.B., Majno, G., Acute inflammation: a review. Am J Path 86:1 (1997), 183–276 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2032041.
2. Melnicoff, M.J., Horan, P.K., Morahan, P.S., Kinetics of changes in peritoneal cell populations following acute inflammation. Cell Immunol 118:1 (1989), 178–191, 10.1016/0008-8749(89)90367-5.
3. Doherty, D.E., Downey, G.P., Worthen, G.S., Haslett, C., Henson, P.M., Monocyte retention and migration in pulmonary inflammation requirement for neutrophils. Lab Invest 59:2 (1988), 200–213 https://europepmc.org/abstract/med/3404972.
4. Kushner, I., Regulation of the acute phase response by cytokines. Persp Boil Med. 36:4 (1993), 611–622, 10.1353/pbm.1993.0004.
5. Kaplanski, G., Marin, V., Montero-Julian, F., Mantovani, A., Farnarier, A.C., IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24:1 (2003), 25–29, 10.1016/S1471-4906(02)00013-3.
6. Scheller, J., Chalaris, A., Schmidt-Arras, D., Rose-John, S., The pro-and anti-inflammatory properties of the cytokine interleukin-6. BBA-Mol Cell Res 1813:5 (2011), 878–888, 10.1016/j.bbamcr.2011.01.034.
7. Weissenbach, J., Chernajovsky, Y., Zeevi, M., et al. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci 77:12 (1980), 7152–7156, 10.1073/pnas.77.12.7152.
8. Zilberstein, A., Ruggieri, R., Korn, J.H., Revel, M., Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J 5:10 (1986), 2529–2537, 10.1002/j.14602075.1986.tb04531.x.
9. De Wit, L., Pierard, D., Derynck, R., De Clercq, E., Fiers, W., Secretory proteins induced in human fibroblasts under conditions used for the production of interferon beta. Proc Natl Acad Sci 79:9 (1982), 2768–2772, 10.1073/pnas.79.9.2768.
10. Haegeman, G., Content, J., Volckaert, G., Derynck, R., Tavernier, J., Fiers, W., Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. FEBS J 159:3 (1986), 625–632, 10.1111/j.1432-1033.1986.tb09931.x.
11. Hirano, T., Taga, T., Nakano, N., et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci 82:16 (1985), 5490–5494, 10.1073/pnas.82.16.5490.
12. Van Snick, J., Cayphas, S., Vink, A., et al. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci 83:24 (1986), 9679–9683, 10.1073/pnas.83.24.9679.
13. Brakenhoff, J.P., De Groot, E.R., Evers, R.F., Pannekoek, H., Aarden, L.A., Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J Immunol 139:12 (1987), 4116–4121 https://www.ncbi.nlm.nih.gov/pubmed/3320204.
14. Nordan, R.P., Pumphrey, J.G., Rudikoff, S., Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1. J Immunol 139:3 (1987), 813–817 https://www.ncbi.nlm.nih.gov/pubmed/3496392.
15. Gauldie, J., Richards, C., Harnish, D., Lansdorp, P., Baumann, H., Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci 84:20 (1987), 7251–7255, 10.1073/pnas.84.20.7251.
16. Ikebuchi, K., Wong, G.G., Clark, S.C., Ihle, J.N., Hirai, Y., Ogawa, M., Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotentialhemopoietic progenitors. Proc Natl Acad Sci 84:24 (1987), 9035–9039, 10.1073/pnas.84.24.9035.
17. Takai, Y., Wong, G.G., Clark, S.C., Burakoff, S.J., Herrmann, S.H., B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 140:2 (1988), 508–512 https://www.ncbi.nlm.nih.gov/pubmed/3257241.
18. Ershler, W.B., Interleukin-6: a cytokine for gerontolgists. J Am Geriatr Soc 41:2 (1993), 176–181, 10.1111/j.1532-5415.1993.tb02054.x.
19. Heinrich, P.C., Behrmann, I., Serge, H.A.A.N., Hermanns, H.M., Müller-Newen, G., Schaper, F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1 (2003), 1–20, 10.1042/bj20030407.
20. Schaper, F., Rose-John, S., Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev 26:5 (2015), 475–487, 10.1016/j.cytogfr.2015.07.004.
21. Garbers, C., Hermanns, H.M., Schaper, F., et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 23:3 (2012), 85–97, 10.1016/j.cytogfr.2012.04.001.
22. Somers, W., Stahl, M., Seehra, J.S., 1.9 Å crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J 16:5 (1997), 989–997, 10.1093/emboj/16.5.989.
23. Briso, E.M., Dienz, O., Rincon, M., Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol 180:11 (2008), 7102–7106, 10.4049/jimmunol.180.11.7102.
24. Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., Scheller, J., The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 90:6–7 (2011), 484–494, 10.1016/j.ejcb.2010.10.007.
25. Varghese, J.N., Moritz, R.L., Lou, M.Z., et al. Structure of the extracellular domains of the human interleukin-6 receptor α-chain. Proc Natl Acad Sci 99:25 (2002), 15959–15964, 10.1073/pnas.232432399.
26. Xu, Y., Kershaw, N.J., Luo, C.S., et al. Crystal Structure of the Entire Ectodomain of gp130 insights into the molecular assembly of the tall cytokine receptor complexes. J Biol Chem 285:28 (2010), 21214–21218.
27. Boulanger, M.J., Chow, D.C., Brevnova, E.E., Garcia, K.C., Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex. Science 300:5628 (2010), 2101–2104, 10.1126/science.1083901.
28. Li, H., Xiao, H., Lin, L., et al. Drug design targeting protein–protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J Med Chem 57:3 (2014), 632–641, 10.1021/jm401144z.
29. Bousoik, E., Aliabadi, H.M., “Do we know jack” about JAK? A closer look at JAK/STAT signaling pathway. Front Oncol 8 (2018), 1–20, 10.3389/fonc.2018.00287.
30. Masjedi, A., Hashemi, V., Hojjat-Farsangi, M., et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother 108 (2018), 1415–1424, 10.1016/j.biopha.2018.09.177.
31. Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., Mills, G.B., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:12 (2015), 988–1004, 10.1038/nrd1902.
32. Ait-Ghezala, G., Volmar, C.H., Frieling, J., et al. CD40 promotion of amyloid beta production occurs via the NF-κB pathway. Eur J Neurosci 25:6 (2007), 1685–1695, 10.1111/j.1460-9568.2007.05424.x.
33. Tanaka, T., Narazaki, M., Kishimoto, T., IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:10 (2014), 1–16, 10.1101/cshperspect.a016295.
34. Takatsuki, F., Okano, A., Suzuki, C., et al. Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. J Immunol 141:9 (1988), 3072–3077 https://www.ncbi.nlm.nih.gov/pubmed/2459240.
35. Ambrosino, D.M., Delaney, N.R., Shamberger, R.C., Human polysaccharide-specific B cells are responsive to pokeweed mitogen and IL-6. J Immunol 144:4 (1990), 1221–1312 https://www.ncbi.nlm.nih.gov/pubmed/2105993.
36. Helle, M., Brakenhoff, J.P., Groot, E.R.D., Aarden, L.A., Interleukin 6 is involved in interleukin 1-induced activities. Europ J Immunol 18:6 (1988), 957–959, 10.1002/eji.1830180619.
37. Renauld, J.C., Vink, A., Van Snick, J., Accessory signals in murine cytolytic T cell responses. Dual requirement for IL-1 and IL-6. J Immunol 143:6 (1989), 1894–1898.
38. Luger, T.A., Krutman, J., Kirnbauer, T., et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol 143:4 (1989), 1206–1209 https://www.ncbi.nlm.nih.gov/pubmed/2787359.
39. Tabibzadeh, S., Kong, Q.F., Babaknia, A., May, L.T., Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. Mol Hum Reprod 1:8 (1995), 407–413, 10.1093/molehr/1.8.407.
40. Hakovirta, H., Syed, V., Jégou, B., Parvinen, M., Function of interleukin-6 as an inhibitor of meiotic DNA synthesis in the rat seminiferous epithelium. Mol Cell Endocrinol 108:1–2 (1995), 193–198, 10.1016/0303-7207(95)03475-M.
41. Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y., Roodman, G.D., IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 144:11 (1988), 4226–4230 https://www.ncbi.nlm.nih.gov/pubmed/2341718.
42. Tamura, T., Udagawa, N., Takahashi, N., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Nat Acad Sci. 90:24 (1993), 11924–11928, 10.1073/pnas.90.24.11924.
43. Girasole, G., Jilka, R.L., Passeri, G., et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89:3 (1992), 883–891, 10.1172/JCI115668.
44. Miyaura, C., Kusano, K., Masuzawa, T., et al. Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. J Bone Miner Res 10:9 (1995), 1365–1373, 10.1002/jbmr.5650100914.
45. Poli, V., Balena, R., Fattori, E., et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:5 (1994), 1189–1196, 10.1002/j.14602075.1994.tb06368.x.
46. Yoshizaki, K., Nishimoto, N., Matsumoto, K., et al. Interleukin 6 and expression of its receptor on epidermal keratinocytes. Cytokine 2:5 (1990), 381–387, 10.1016/10434666(90)90069-6.
47. Hill, R.J., Warren, M.K., Stenberg, P., et al. Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood 77:1 (1991), 42–48 https://www.ncbi.nlm.nih.gov/pubmed/1984802.
48. Chiu, C.P., Lee, F., IL-6 is a differentiation factor for M1 and WEHI-3B myeloid leukemic cells. J Immuno 142:6 (1989), 1909–1915 https://www.ncbi.nlm.nih.gov/pubmed/2784140.
49. Lotem, J., Shabo, Y., Sachs, L., Clonal variation in susceptibility to differentiation by different protein inducers in the myeloid leukemia cell line M1. Leukemia 3:11 (1989), 804–807 https://www.ncbi.nlm.nih.gov/pubmed/2509827.
50. Hama, T., Miyamoto, M., Tsukui, H., Nishio, C., Hatanaka, H., Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci Lett 104:3 (1989), 340–344, 10.1016/0304-3940(89)90600-9.
51. Keller, E.T., Wanagat, J., Ershler, W.B., Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1 (1996), d340–d357, 10.2741/a136.
52. Dethlefsen, C., Hojfeldt, G., Hojman, P., The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138:3 (2013), 657–664, 10.1007/s10549-013-2488-z.
53. Culig, Z., Puhr, M., Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 360:1–2 (2012), 52–58, 10.1016/j.mce.2011.05.033.
54. Macciò, A., Madeddu, C., The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications-a review. J Mol Med 91:12 (2013), 1355–1368, 10.1007/s00109-013-1080-7.
55. Miura, T., Mitsunaga, S., Ikeda, M., et al. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas 44:5 (2015), 756–763, 10.1097/MPA.0000000000000335.
56. Chang, C.H., Hsiao, C.F., Yeh, Y.M., et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 132:9 (2013), 1977–1985, 10.1002/ijc.27892.
57. Altundag, O., Altundag, K., Gunduz, E., Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J Clin Oncol, 23(5), 2005, 10.1200/JCO.2005.05.155 1044–1044.
58. Wei, L.H., Kuo, M.L., Chen, C.A., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene, 22(10), 2003, 1517, 10.1038/sj.onc.1206226.
59. Singh, U., Shevra, C.R., Singh, S., Singh, N., Kumar, S., Rai, M., Interleukin-6 and interleukin-4 levels in multiple myeloma and correlation of interleukin-6 with β2 microglobulin and serum creatinine. Clinical Cancer Invest J, 4(2), 2015, 211, 10.4103/2278-0513.148963.
60. Johnston, P.A., Grandis, J.R., STAT3 signaling: anticancer strategies and challenges. Mol Interv, 11(1), 2011, 18, 10.1124/mi.11.1.4.
61. Zhang, X., Zhang, J., Wei, H., Tian, Z., STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep 17:6 (2007), 1377–1382, 10.3892/or.17.6.1377.
62. Wang, X.H., Liu, B.R., Qu, B., et al. Silencing STAT3 may inhibit cell growth through regulating signalling pathway, telomerase, cell cycle, apoptosis and angiogenesis in hepatocellular carcinoma: potential uses for gene therapy. Neoplasma 58:2 (2011), 158–171, 10.4149/neo_2011_02_158.
63. Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., Yu, H., STAT3 mediates myeloid cell–dependent tumor angiogenesis in mice. J Clin Invest 118:10 (2008), 3367–3377, 10.1172/JCI35213.
64. Yang, X.M., Wang, Y.S., Zhang, J., et al. Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1α and VEGF in laser-induced rat choroidal neovascularization. Invest Ophthalmol Vis Sci 50:4 (2009), 1873–1879, 10.1167/iovs.08-2591.
65. Trotman, L.C., Pandolfi, P.P., PTEN and p53: who will get the upper hand. Cancer Cell 3:2 (2003), 97–99, 10.1016/S1535-6108(03)00022-9.
66. Liu, W., Zhou, Y., Reske, S.N., Shen, C., PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res 28:6A (2008), 3613–3619 https://www.ncbi.nlm.nih.gov/pubmed/19189642?dopt=Abstract.
67. Wullschleger, S., Loewith, R., Hall, M.N., TOR signaling in growth and metabolism. Cell 124:3 (2006), 471–484, 10.1016/j.cell.2006.01.016.
68. Boye, K., Grotterod, I., Aasheim, H.C., Hovig, E., Mælandsmo, G.M., Activation of NF-κB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. Int J Cancer 123:6 (2008), 1301–1310, 10.1002/ijc.23617.
69. Trikha, M., Corringham, R., Klein, B., Rossi, J.F., Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9:13 (2003), 4653–4665 https://www.ncbi.nlm.nih.gov/pubmed/14581334.
70. Unver, N., McAllister, F., IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev 41 (2018), 10–17, 10.1016/j.cytogfr.2018.04.004.
71. McKay, K.A., Tremlett, H., The systematic search for risk factors in multiple sclerosis. Lancet Neurol 14:3 (2015), 237–238, 10.1016/S1474-4422(15)70015-3.
72. Petkovic, F., Castellano, B., The role of interleukin-6 in central nervous system demyelination. Neural Regen Res 11:12 (2016), 1922–1923, 10.4103/1673-5374.195273.
73. Krei, K., Fredrikson, S., Fontana, A., Link, H., Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 31:2 (1991), 147–153, 10.1016/0165-5728(91)90020-8.
74. Wullschleger, A., Kapina, V., Molnarfi, N., et al. Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. PLoS ONE, 8(8), 2013, e72399, 10.1371/journal.pone. 0072399.
75. Campbell, I.L., Erta, M., Lim, S.L., et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 34:7 (2014), 2503–2513, 10.1523/JNEUROSCI.283013.2014.
76. Quintana, A., Müller, M., Frausto, R.F., et al. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol 183:3 (2009), 2079–2088, 10.4049/jimmunol.0900242.
77. Sareda, S., Fujimoto, M., Mihara, M., et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci 105:26 (2008), 9041–9046, 10.1073/pnas.0802218105.
78. Nakajima, T., Kinoshita, S., Sasagawa, T., et al. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci 90:6 (1993), 2207–2211, 10.1073/pnas.90.6.2207.
79. Quintanilla, R.A., Orellana, D.I., González-Billault, C., Maccioni, R.B., Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 295:1 (2004), 245–257, 10.1016/j.yexcr.2004.01.002.
80. Yoshizaki, K., Murayama, S., Ito, H., Koga, T., The role of interleukin-6 in castleman disease. Hematol Oncol Clin North Am 32:1 (2018), 23–36, 10.1016/j.hoc. 2017.09.003.
81. Chung, S.J., Kwon, Y.J., Park, M.C., Park, Y.B., Lee, S.K., The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 52:1 (2011), 113–120, 10.3349/ymj.2011.52.1.113.
82. Mihara, M., Kotoh, M., Nishimoto, N., et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol 98:3 (2001), 319–326, 10.1006/clim.2000.4989.
83. Nakahara, H., Song, J., Sugimoto, M., et al. Anti–interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:6 (2003), 1521–1529, 10.1002/art.11143.
84. Katsume, A., Saito, H., Yamada, Y., et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20:6 (2002), 304–311, 10.1006/cyto.2002.2012.
85. Tanaka, T., Ogata, A., Kishimoto, T., Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatol Curr Res S4 (2013), 2161–11149, 10.4172/2161-1149.S4-002.
86. Nemeth, E., Rivera, S., Gabayan, V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 113:9 (2004), 1271–1276, 10.1172/JCI20945.
87. Zhao, N., Zhang, A.S., Enns, C.A., Iron regulation by hepcidin. J Clin Invest. 123:6 (2013), 2337–2343, 10.1172/JCI67225.
88. Bamias, G., Nyce, M.R., Sarah, A., Cominelli, F., New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 143:12 (2005), 895–904, 10.7326/0003-4819-143-12-200512200-00007.
89. Ishihara, K., Hirano, T., IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13:4–5 (2002), 357–368, 10.1016/S1359-6101(02)00027-8.
90. Mitsuyama, K., Toyonaga, A., Sasaki, E., et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36:1 (1995), 45–49, 10.1136/gut.36.1.45.
91. Gross, V., Andus, T., Caesar, I., Roth, M., Schölmerich, J., Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterol. 102:2 (1992), 514–519, 10.1016/00165085(92)90098-j.
92. Reinisch, W., Gasché, C., Tillinger, W., et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 94:8 (1999), 2156–2164, 10.1111/j.1572-241.1999.01288.x.
93. Mudter, J., Neurath, M.F., IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 13:8 (2007), 1016–1023, 10.1002/ibd.20148.
94. Ito, H., Takazoe, M., Fukuda, Y., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterol. 126:4 (2004), 989–996, 10.1053/j.gastro.2004.01.012.
95. Celli, B.R., Locantore, N., Yates, J., et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 185:10 (2012), 1065–1072, 10.1164/rccm.201110-1792OC.
96. Yokoyama, A., Kohno, N., Fujino, S., et al. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med 151:5 (1995), 1354–1358, 10.1164/ajrccm.151.5.7735584.
97. Doganci, A., Eigenbrod, T., Krug, N., et al. The IL-6R α chain controls lung CD4+ CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 115:2 (2005), 313–325, 10.1172/JCI22433.
98. Rincon, M., Irvin, C.G., Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci, 8(9), 2012, 1281, 10.7150/ijbs.4874.
99. He, J.Q., Foreman, M.G., Shumansky, K., et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax 64:8 (2009), 698–704, 10.1136/thx.2008.111278.
100. Rubbert-Roth, A., Furst, D.E., Nebesky, J.M., Jin, A., Berber, E., A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther 5:1 (2018), 21–42, 10.1007/s40744-018-0102-x.
101. Kawai, M., Hagihara, K., Hirano, T., et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology 48:3 (2008), 318–319, 10.1093/rheumatology/ken468.
102. Dijkgraaf, E.M., Santegoets, S.J.A.M., Reyners, A.K.L., et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Ann Oncol 26:10 (2015), 2141–2149, 10.1093/annonc/mdv309.
103. Sieper, J., Braun, J., Kay, J., et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheumatic Dis 74:6 (2015), 1051–1057, 10.1136/annrheumdis-2013-204963.
104. Smolen, J.S., Weinblatt, M.E., Sheng, S., Zhuang, Y., Hsu, B., Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheumatic Dis 73:9 (2014), 1616–1625, 10.1136/annrheumdis-2013-205137.
105. Rovin, B.H., van Vollenhoven, R.F., Aranow, C., et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol 68:9 (2016), 2174–2183, 10.1002/art.39722.
106. San-Miguel, J., Bladé, J., Shpilberg, O., et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma. Blood 123:26 (2014), 4136–4142, 10.1182/blood-2013-12-546374.
107. Weinblatt, M.E., Mease, P., Mysler, E., et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol 67:10 (2015), 2591–2600, 10.1002/art.39249.
108. Danese, S., Vermeire, S., Hellstern, P., et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut 68:1 (2019), 40–48, 10.1136/gutjnl-2017-314562.
109. Li, C., Shoji, S., Beebe, J., Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. Br J Clin Pharmacol 84:9 (2018), 2059–2074, 10.1111/bcp.13641.
110. Clinical trials registered in ClinicalTrials.gov. https://clinicaltrials.gov; 2019 Accessed on 01 October 2019.
111. Guha, M., Mackman, N., LPS induction of gene expression in human monocytes. Cellular Signal 13:2 (2001), 85–94, 10.1016/S0898-6568(00)00149-2.
112. Tagat, J.R., Nazareno, D.V., McCombie, S.W., Barton, B.E., Shortall, J., Jackson, J., Synthetic inhibitors of interleukin-6 I: 2, 3, 7, 8-tetrahydro-4-aryl-1H-cyclopent [e] imidazo [1, 2-a]-pyridin-5 (6H)-one and related compounds. Bioorg Med Chem Lett 5:18 (1995), 2139–2142, 10.1016/0960-894X(95)00362-W.
113. Tagat, J.R., McCombie, S.W., Barton, B.E., Jackson, J., Shortall, J., Synthetic inhibitors of interleukin-6 II: 3, 5-diaryl pyridines and meta-terphenyls. Bioorg Med Chem Lett 5:18 (1995), 2143–2146, 10.1016/0960-894X(95)00363-X.
114. Hayashi, M., Kim, Y.P., Takamatsu, S., et al. Madindoline, a novel inhibitor of IL-6 activity from Streptomyces sp. K93–0711. J Antibiot. 49:11 (1996), 1091–1095 https://www.ncbi.nlm.nih.gov/pubmed/8982336/.
115. Yamamoto, D., Sunazuka, T., Hirose, T., Kojima, N., Kaji, E., Omura, S., Design, synthesis, and biological activities of madindoline analogues. Bioorg Med Chem Lett 16:10 (2006), 2807–2811, 10.1016/j.bmcl.2006.01.107.
116. Hosokawa, S., Sekiguchi, K., Hayase, K., Hirukawa, Y., Kobayashi, S., Total synthesis of madindoline A. Tetrahedron Lett 41:33 (2000), 6435–6439, 10.1016/S0040-4039(00)00939-4.
117. Saleh, A.Z., Greenman, K.L., Billings, S., Van Vranken, D.L., Krolewski, J.J., Binding of madindoline A to the extracellular domain of gp130. Biochemistry 44:32 (2005), 10822–10827, 10.1021/bi050439+.
118. Bharate, S.B., Mahajan, T.R., Gole, Y.R., et al. Synthesis and evaluation of pyrazolo [3, 4-b] pyridines and its structural analogues as TNF-α and IL-6 inhibitors. Bioorg Med Chem 16:15 (2008), 7167–7176, 10.1016/j.bmc.2008.06.042.
119. Kahlon, D.K., Lansdell, T.A., Fisk, J.S., et al. Nuclear factor-κB mediated inhibition of cytokine production by imidazoline scaffolds. J Med Chem 52:5 (2009), 1302–1309, 10.1021/jm8013162.
120. Kahlon, D.K., Lansdell, T.A., Fisk, J.S., Tepe, J.J., Structural–activity relationship study of highly-functionalized imidazolines as potent inhibitors of nuclear transcription factor-κB mediated IL-6 production. Bioorg Med Chem 17:8 (2009), 3093–3103, 10.1016/j.bmc.2009.03.002.
121. Bandgar, B.P., Patil, S.A., Totre, J.V., et al. Synthesis and biological evaluation of nitrogen-containing benzophenoneanalogues as TNF-α and IL-6 inhibitors with antioxidant activity. Bioorg Med Chem Lett 20:7 (2010), 2292–2296, 10.1016/j.bmcl.2010.02.001.
122. Bandgar, B., Hote, B., Gangwal, R., Sangamwar, A., Synthesis biological evaluation, and pharmacokinetic profiling of benzophenone derivatives as tumor necrosis factor-alpha and interleukin-6 inhibitors. Med Chem Res 21:10 (2012), 3177–3181, 10.1007/s00044-011-9856-1.
123. Bandgar, B.P., Patil, S.A., Korbad, B.L., Nile, S.H., Khobragade, C.N., Synthesis and biological evaluation of β-chloro vinyl chalcones as inhibitors of TNF-α and IL-6 with antimicrobial activity. Eur J Med Chem 45:6 (2010), 2629–2633, 10.1016/j.ejmech.2010.01.050.
124. Wu, J., Li, J., Cai, Y., et al. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J Med Chem 54:23 (2011), 8110–8123, 10.1021/jm200946h.
125. Upadhyay, K., Bavishi, A., Thakrar, S., et al. Synthesis and biological evaluation of 4-styrylcoumarin derivatives as inhibitors of TNF-α and IL-6 with anti-tubercular activity. Bioorg Med Chem Lett 21:8 (2011), 2547–2549, 10.1016/j.bmcl.2011.02.016.
126. Chaulet, C., Croix, C., Alagille, D., et al. Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors. Bioorg Med Chem Lett 21:3 (2011), 1019–1022, 10.1016/j.bmcl.2010.12.031.
127. Guirado, A., Sánchez, J.I.L., Ruiz-Alcaraz, A.J., Bautista, D., Gálvez, J., Synthesis and biological evaluation of 4-alkoxy-6, 9-dichloro [1, 2, 4] triazolo [4, 3-a] quinoxalines as inhibitors of TNF-α and IL-6. Eur J Med Chem 54 (2012), 87–94, 10.1016/j.ejmech.2012.04.035.
128. Guirado, A., Sánchez, J.I.L., Ruiz-Alcaraz, A.J., García-Peñarrubia, P., Bautista, D., Gálvez, J., First synthesis and biological evaluation of 4-amino-2-aryl-6, 9-dichlorobenzo [g] pteridines as inhibitors of TNF-α and IL-6. Eur J Med Chem 66 (2013), 269–275, 10.1016/j.ejmech.2013.05.020.
129. Furman, S., Nissim-Bardugo, E., Zeeli, S., et al. Synthesis and in vitro evaluation of anti-inflammatory activity of ester and amine derivatives of indoline in RAW 264.7 and peritoneal macrophages. Bioorg Med Chem Lett 24:10 (2014), 2283–2287, 10.1016/j.bmcl.2014.03.081.
130. Singh, P., Kaur, S., Sharma, A., Kaur, G., Bhatti, R., TNF-α and IL-6 inhibitors: Conjugates of N-substituted indole and aminophenylmorpholin-3-one as anti-inflammatory agents. Eur J Med Chem 140 (2017), 92–103, 10.1016/j.ejmech.2017.09.003.
131. Li, J., Huang, W., Zhang, H., Wang, X., Zhou, H., Synthesis of andrographolide derivatives and their TNF-α and IL-6 expression inhibitory activities. Bioorg Med Chem Lett 17:24 (2007), 6891–6894, 10.1016/j.bmcl.2007.10.009.
132. Kang, T.H., Han, N.R., Kim, H.M., Jeong, H.J., Blockade of IL-6 secretion pathway by the sesquiterpenoidatractylenolide III. J Nat Prod 74:2 (2011), 223–227, 10.1021/np100686a.
133. Jain, S.K., Singh, S., Khajuria, A., et al. Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity. J Med Chem 57:16 (2014), 7085–7097, 10.1021/jm500901e.
134. Galvez-Llompart, M., Zanni, R., García-Domenech, R., Modeling natural anti- inflammatory compounds by molecular topology. Int J Mol Sci 12:12 (2011), 9481–9503, 10.3390/ijms12129481.
135. Wang, W., Lee, T.G., Patil, R.S., et al. Monanchosterols A and B, bioactive bicyclo [4.3. 1] steroids from a Korean sponge Monanchora sp. J Nat Prod 78:3 (2014), 368–373, 10.1021/np500760v.
136. Kamano, Y., Nogawa, T., Yamashita, A., et al. Isolation and structure of a 20, 21-epoxybufenolide series from “Ch'an Su”. J Nat Prod 65:7 (2002), 1001–1005, 10.1021/np0200360.
137. Boos, T.L., Cheng, K., Greiner, E., Deschamps, J.R., Jacobson, A.E., Rice, K.C., Configurational reassignment and improved preparation of the competitive IL-6 receptor antagonist 20 R, 21 R-Epoxyresibufogenin-3-formate. J Nat Prod 75:4 (2012), 661–668, 10.1021/np2008957.
138. Adachi, Y., Yoshio-Hoshino, N., Nishimoto, N., The blockade of IL-6 signaling in rational drug design. Curr Pharm Des 14:12 (2008), 1217–1224, 10.2174/138161208784246072.
139. Zinzalla, G., Haque, M.R., Basu, B.P., et al. A novel small-molecule inhibitor of IL-6 signalling. Bioorg Med Chem Lett 20:23 (2010), 7029–7032, 10.1016/j.bmcl.2010.09.117.
140. Lee, C., Lee, J.W., Jin, Q., et al. Isolation and characterization of dammarane-type saponins from Gynostemma pentaphyllum and their inhibitory effects on IL-6-induced STAT3 activation. J Nat Prod 78:5 (2015), 971–976, 10.1021/np500803e.
141. Singh, S., Gajulapati, V., Gajulapati, K., et al. Structure–activity relationship study of a series of novel oxazolidinone derivatives as IL-6 signaling blockers. Bioorg Med Chem Lett 26:4 (2016), 1282–1286, 10.1016/j.bmcl.2016.01.016.
142. Lai, C.S., Yang, G., Li, S., et al. 3′-Hydroxypterostilbene suppresses colitis-associated tumorigenesis by inhibition of IL-6/STAT3 signaling in mice. J Agri Food Chem. 65:44 (2017), 9655–9664, 10.1021/acs.jafc.7b03712.
143. Kim, D., Won, H.Y., Hwang, E.S., Kim, Y.K., Choo, H.Y.P., Synthesis of benzoxazole derivatives as interleukin-6 antagonists. Bioorg Med Chem 25:12 (2017), 3127–3134, 10.1016/j.bmc.2017.03.072.
144. Choo HYP, Kim YK, Choi JH, Kim JA. Benzoxazole derivatives having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing the same. US Patent; US8614240B2; 2013.
145. Fathi, M.A.A., El-Hafeez, A.A.A., Abdelhamid, D., Abbas, S.H., Montano, M.M., Abdel-Aziz, M., 1, 3, 4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities. Bioorg Chem 84 (2019), 150–163, 10.1016/j.bioorg.2018.11.032.
146. Lin, C.M., Shyu, K.G., Wang, B.W., Chang, H., Chen, Y.H., Chiu, J.H., Chrysin suppresses IL-6-induced angiogenesis via down-regulation of JAK1/STAT3 and VEGF: an in vitro and in ovo approach. J Agri Food Chem 58:11 (2010), 7082–7087, 10.1021/jf100421w.
147. Lee, S.J., Jang, H.J., Kim, Y., et al. Inhibitory effects of IL-6-induced STAT3 activation of bio-active compounds derived from Salvia plebeia R. Br. Process Biochem 51:12 (2016), 2222–2229, 10.1016/j.procbio.2016.09.003.
148. Lim, H.J., Jang, H.J., Bak, S.G., et al. In vitro inhibitory effects of cirsiliol on IL-6-induced STAT3 activation through anti-inflammatory activity. Bioorg Med Chem Lett 29:13 (2019), 1586–1592, 10.1016/j.bmcl.2019.04.053.
149. Kumar, P., Rawat, A., Keshari, A.K., et al. Antiproliferative effect of isolated isoquinoline alkaloid from Mucuna pruriens seeds in hepatic carcinoma cells. Nat Prod Res 30:4 (2016), 460–463, 10.1080/14786419.2015.1020489.
150. Kumar, P., Singh, A.K., Raj, V., et al. 6, 7-dimethoxy-1, 2, 3, 4-tetrahydro-isoquinoline-3-carboxylic acid attenuates heptatocellular carcinoma in rats with NMR-based metabolic perturbations. Future Sci OA, 3(3), 2017, FSO202, 10.4155/fsoa-2017-0008.
151. Mishra, P., Raj, V., Bhadauria, A.S., et al. 6, 7-dimethoxy-1, 2, 3, 4-tetrahydro-isoquinoline-3-carboxylic acid attenuates colon carcinogenesis via blockade of IL-6 mediated signals. Biomed Pharmacother 100 (2018), 282–295, 10.1016/j.biopha.2018.02.009.
152. Qi, F., Inagaki, Y., Gao, B., et al. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas-and mitochondria-mediated pathways. Cancer Sci 102:5 (2011), 951–958, 10.1111/j.1349-7006.2011.01900.x.
153. Xiang, R.F., Wang, Y., Zhang, N., et al. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis, 8(5), 2017, e2776, 10.1038/cddis.2017.188.
154. Wu, X.Y., Tian, F., Su, M.H., et al. BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway. Int Immunopharmacol 64 (2018), 24–32, 10.1016/j.intimp.2018.08.016.
155. Wang, N., Li, D.Y., Niu, H.Y., Zhang, Y., He, P., Wang, J.H., 2-hydroxy-3-methylanthraquinone from Hedyotis diffusa Willd induces apoptosis in human leukemic U937 cells through modulation of MAPK pathways. Arch Pharm Res 36 (2013), 752–7588, 10.1007/s12272-013-0096-4.
156. Liu, Z., Liu, M., Liu, M., Li, J., Methylanthraquinone from Hedyotis diffusa WILLD induces Ca2+-mediated apoptosis in human breast cancer cells. Toxicol In Vitro 24:1 (2010), 142–147, 10.1016/j.tiv.2009.08.002.
157. Shi, Y., Wang, C.H., Gong, X.G., Apoptosis-Inducing Effects of Two Anthraquinones from Hedyotis diffusa W ILLD. Biol Pharm Bull 31:6 (2008), 1075–1078, 10.1248/bpb.31.1075.
158. Sun, C., Yang, J., Cheng, H.B., et al. 2-Hydroxy-3-methylanthraquinone inhibits lung carcinoma cells through modulation of IL-6-induced JAK2/STAT3 pathway. Phytomedicine, 61, 2019, 152848, 10.1016/j.phymed.2019.152848.
159. Singh, A.K., Raj, V., Rai, A., Keshari, A.K., Saha, S., Indole-fused benzooxazepines: a new structural class of anticancer agents. Future Sci OA, 3(1), 2017, FSO168, 10.4155/fsoa-2016-0079.
160. Singh, A.K., Bhadauria, A.S., Kumar, U., et al. Novel fused oxazepino-indoles (FOIs) attenuate liver carcinogenesis via IL-6/JAK2/STAT3 signaling blockade as evidenced through data-based mathematical modeling. Life Sci 201 (2018), 161–172, 10.1016/j.lfs.2018.02.029.
161. Costa-Pereira, A.P., Regulation of IL-6-type cytokine responses by MAPKs. Biochem Soc Trans 42 (2014), 59–62, 10.1042/BST20130267.
162. Jung, Y.J., Kim, B.O., Kwak, J.H., Pyo, S., Inhibitory effect of methyl 2-(4′-methoxy-4′-oxobutanamide) benzoate from jerusalem artichoke (helianthus tuberosus) on the inflammatory paracrine loop between macrophages and adipocytes. J Agric Food Chem 64:49 (2016), 9317–9325, 10.1021/acs.jafc.6b03407.